embryonal carcinoma
teratocarcinoma
seminoma
teprotumumab
taplitumomab
malignin
tabalumab
oportuzumab monatox
amivantamab
mapatumumab
alacizumab
catumaxomab
ertumaxomab
testiculomata
tisotumab
dalotuzumab
-mel-
sibrotuzumab
pseudocapsule
caplacizumab
tumorous
oncotropic
oncoimmunology
pintumomab
edrecolomab
-gov-
iratumumab
citatuzumab bogatox
neoplastic cell
cergutuzumab
-mab
agonistic monoclonal antibody
zalutumumab
immunoenzymatic
immunochemiluminometric
monoantibody
-mar-
microlymphocytotoxicity
histiocytoma
durvalumab
apolizumab
antimonoclonal
ensituximab
pritumumab
colosphere
oncocytoma
onco-
malignancy
nimotuzumab
nacolomab tafenatox